RGNX (Regenxbio) Cyclically Adjusted Book per Share: $11.38 (As of Mar. 2026)


RGNX Regenxbio Inc RGNX
54 GF Score
Price $15.03
GF Value $14.49
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Regenxbio Cyclically Adjusted Book per Share?

Regenxbio RGNX -1.31% 54 Cyclically Adjusted Book per Share is $11.38 as of Mar. 2026. GuruFocus rates RGNX with a GF Score™ of 54/100 and a GF Value™ of $14.49 (Fairly Valued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Regenxbio's adjusted book value per share for the three months ended in Mar. 2026 was $0.408. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $11.38 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Regenxbio's average Cyclically Adjusted Book Growth Rate was -2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-09), Regenxbio's current stock price is $15.03. Regenxbio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $11.38. Regenxbio's Cyclically Adjusted PB Ratio of today is 1.32.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regenxbio was 1.68. The lowest was 0.50. And the median was 0.83.


Regenxbio  (NAS:RGNX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regenxbio's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=15.03/11.38
=1.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regenxbio was 1.68. The lowest was 0.50. And the median was 0.83.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Regenxbio Cyclically Adjusted Book per Share Related Terms


Regenxbio Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Regenxbio's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio Cyclically Adjusted Book per Share Chart

Regenxbio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 11.73 11.43

Regenxbio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.72 11.82 11.69 11.43 11.38

RGNX vs ALT, ASMB, CTNM: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted PB Ratio falls into.


RGNX
54GF Score
Regenxbio Inc RGNX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regenxbio Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regenxbio's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.408/330.2130*330.2130
=0.408

Current CPI (Mar. 2026) = 330.2130.

Regenxbio Quarterly Data

Book Value per Share CPI Adj_Book
201606 7.413 241.018 10.156
201609 6.807 241.428 9.310
201612 6.109 241.432 8.355
201703 7.039 243.801 9.534
201706 6.861 244.955 9.249
201709 6.257 246.819 8.371
201712 5.849 246.524 7.835
201803 9.384 249.554 12.417
201806 9.829 251.989 12.880
201809 13.838 252.439 18.101
201812 14.088 251.233 18.517
201903 13.303 254.202 17.281
201906 13.458 256.143 17.350
201909 12.714 256.759 16.351
201912 12.170 256.974 15.639
202003 11.297 258.115 14.453
202006 10.669 257.797 13.666
202009 11.113 260.280 14.099
202012 10.080 260.474 12.779
202103 13.046 264.877 16.264
202106 11.920 271.696 14.487
202109 10.793 274.310 12.993
202112 17.845 278.802 21.136
202203 16.046 287.504 18.430
202206 14.605 296.311 16.276
202209 13.024 296.808 14.490
202212 11.922 296.797 13.264
202303 10.701 301.836 11.707
202306 9.304 305.109 10.070
202309 8.254 307.789 8.855
202312 7.078 306.746 7.619
202403 7.966 312.332 8.422
202406 7.062 314.175 7.423
202409 6.085 315.301 6.373
202412 5.240 315.605 5.483
202503 5.471 319.799 5.649
202506 4.241 322.561 4.342
202509 3.190 324.800 3.243
202512 2.019 324.054 2.057
202603 0.408 330.213 0.408

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $11.38 mean?
Regenxbio (RGNX) has a Cyclically Adjusted Book per Share of $11.38 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Regenxbio and its competitors.
Is Regenxbio's Cyclically Adjusted Book per Share too high?
Regenxbio's current Cyclically Adjusted Book per Share is $11.38. Overall, Regenxbio has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Regenxbio's Cyclically Adjusted Book per Share compare to ALT and ASMB?
Regenxbio's Cyclically Adjusted Book per Share of $11.38 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Regenxbio and its competitors. Regenxbio's current Cyclically Adjusted Book per Share is $11.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenxbio stock overvalued right now?
Based on GuruFocus' analysis, Regenxbio (RGNX) is currently considered Fairly Valued. The stock's GF Value™ is $14.49, compared to a current price of $15.03 — trading 3.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is $11.38. Regenxbio's overall GF Score™ is 54/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Regenxbio (RGNX), the current Cyclically Adjusted Book per Share is $11.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be overvalued. The current stock price of $15.03 is trading 3.7% above its estimated GF Value™ of $14.49. GuruFocus considers Regenxbio to be Fairly Valued.

Key valuation signals for RGNX:

  • Cyclically Adjusted Book per Share: $11.38
  • GF Value™: $14.49 vs. price of $15.03 (3.7% above fair value)
  • GF Score™: 54/100 with 9 warning signs

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
54GF Score

Get the complete analysis for RGNX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.03
Price
$14.49
GF Value